Monday, July 16, 2018
News
NEWS HOME
»
PRESS RELEASES

AHF: 'Shameless' Gilead Hikes Key AIDS Drug Pricing 6.9% Despite Recent Patent Expiration
  SocialTwist Tell-a-Friend  
   


Date: 11-01-2018 12:48PM
Source: AIDS Healthcare Foundation
Category: General, Consumer Interest, Science & Research, Healthcare & Biotechnology, Pharmaceutical
Location: Los Angeles, United States

Business Wire India

AIDS Healthcare Foundation (AHF), the largest global AIDS organization and a vocal critic of runaway drug pricing and drug profiteering, today blasted Gilead Sciences, Inc. over newly instituted price hikes of 6.9% on three key HIV/AIDS treatments despite the fact that the patent for a key component of each treatment—tenofovir—expired in mid-December.

AHF branded Gilead’s latest pricing action a shameless move by what one expert called “perhaps the most ethically challenged drug company,” in the drug pricing documentary, “Your Money or Your Life.”

In October 2017, as patent expiration loomed for Gilead, AHF called on Gilead to reduce the price of its tenofovir-based drug regimens—including Truvada—by as much as 90%.

The California drug company has made billions off of sales of its tenofovir-based drugs since the FDA first approved Gilead’s tenofovir disoproxil fumarate (TDF), branded as Viread, on October 26, 2001. That patent expired on December 15, 2017, with the patent on a pediatric version of the drug set to expire in early 2018. All the while Gilead simultaneously sought to ‘evergreen’ and manipulate the patent extension process.

“It is nothing short of grotesque that Gilead raised the price of Truvada by 6.9% despite the fact that it is now off patent and generic,” said Michael Weinstein, President of AIDS Healthcare Foundation. “This is a lifesaving HIV/AIDS treatment that they have already made billions off of and they are now trying to squeeze the well dry. Also, if Gilead is truly committed to providing and enhancing access to Truvada for use as pre-exposure prophylaxis or PrEP to prevent HIV acquisition by uninfected individuals, it is unconscionable for them to also charge this steep price on a now generic medicine. We call on other AIDS and community groups nationwide to join us in calling on Gilead to reduce its pricing, and also loudly renew our October call on Gilead to reduce the price of its tenofovir-based drug regimens—including Truvada—by 90% as well as on other combination therapies using tenofovir that Gilead makes in partnership with companies like BMS and Janssen.”

Since FDA approval of the drug in 2001, the TDF formulation of tenofovir has become a cornerstone of other big money Gilead combination HIV/AIDS treatment therapies beyond Viread, including:

  • Atripla (efavirenz + tenofovir disoproxil fumarate + emtricitabine—made in partnership with Bristol-Myers Squibb);
  • Complera (rilpivirine + tenofovir disoproxil fumarate + emtricitabine—made in partnership with Janssen Theraputics);
  • Stribild, the four-drug-in-one tablet (elvitegravir + cobicistat + tenofovir disoproxil fumarate + emtricitabine);
  • Truvada (tenofovir disoproxil fumarate + emtricitabine), Gilead’s blockbuster HIV/AIDS treatment that is also the medication component used for pre-exposure prophylaxis (PrEP) to prevent HIV acquisition; and
  • Viread (tenofovir disoproxil fumarate or ‘TDF’ - previously cited above.

In February 2016, AHF filed a lawsuit against Gilead over its manipulation of the patent system in order to derail competition to its HIV medicines. As reported at the time by Ed Silverman on the health news service, STAT, “At issue is tenofovir, or TDF, which is a cornerstone of the combination HIV treatments that Gilead sells. The patent on the TDF compound expires in December 2017 and Gilead hopes to replace it with a modified version known as TAF. The patent on TAF doesn’t expire until May 2022, and the prospect of nearly five more years of sales without generic competition is extremely valuable.”

He also noted, “There is another important difference between the two compounds — TAF is more potent and causes fewer side effects, notably bone damage and kidney toxicity.”

In 2014, in anticipation of Viread’s upcoming patent expiration, Gilead pulled a much more efficacious 30mg lower dose version of Viread off its development shelf and instead began the evergreening process by filing its first New Drug Application (NDA) for the modified Viread molecule, tenofovir alafenamide, or TAF (later branded Vemlidy).

It should be noted that Teva, an Israeli multinational pharmaceutical company and generic drug manufacturer, is allowed to begin production of a generic version of Viread as of December 15, 2017, resulting from its litigation against Gilead. Truvada, which contains the older version of Viread combined with a second Gilead drug called Emtriva, can also go generic as of December 2017.

What is most telling about Gilead’s corporate conscience—or lack thereof—is that after many years of incredible successes, this newer TAF version of Viread, which has a significantly better adverse event profile (particularly regarding renal side effects that impact African Americans much more) was reportedly left on the shelf post-development by Gilead Sciences for years. The reason for doing so is obvious: to maximize profits via the evergreening process by waiting until just the right time to begin filing new drug applications for all previously approved combination therapies. This effectively extends patent life of Gilead’s drug portfolio and greatly enhances the profit margins for Gilead.

AIDS Healthcare Foundation (AHF), the largest global AIDS organization, currently provides medical care and/or services to more than 855,000 individuals in 39 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Eastern Europe. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare.



CONTACTS :

AIDS Healthcare Foundation
Ged Kenslea
Senior Director, Communications
Telephone: (323) 308-1833
Mobile: (323) 791-5526
gedk@aidshealth.org

More Press Releases

Alipay and Singapore Tourism Board join hands to boost Chinese tourist spending

New Study Investigates the Utility of Masimo PVi® as Part of Goal-Directed Fluid Management in Patients Undergoing Colorectal Surgery

IUIH Invites ICT Enterprises to Deliver Over 1 Billion USD Worth of IT Infra and Services for Its Digital Hospitals and Clinics

TIME CyberMedia Concludes Its 3rd International Healthcare Awards, 2018 & Conference in New Delhi

RG Stone Discusses the Causes and Treatment Options for Kidney Stones During Pregnancy

Rolls-Royce Motor Cars Announces New Regional PR & Communications Manager for Middle East, Africa & India

Prudent Corporate Advisory Services Offering Minority Stake to TA Associates

Market Xcel Enters the Big Data Analytics Arena

TA Associates Announces Minority Investment in Prudent Corporate Advisory Services

Wipro Cited as a Leader in Gartner’s Magic Quadrant for Data Center Outsourcing and Hybrid Infrastructure Managed Services, North America

MetLife Selects Lucep as Winner of collab 3.0 EMEA

Contactless Technology Powers Fifty Percent of Purchases at 2018 FIFA World Cup Russia™

Brazil Approves AerSafe for Airbus 321 Aircraft to Comply with Fuel Tank Flammability Reduction Rule

Toyoda Gosei Enhances Technical Development Operations in India

Blockchain-based Adents NovaTrack Issues Token to Standardize Access to Comprehensive Supply Chain Traceability

See Where the Future Unfolds at the IBC2018 Leaders’ Forum

Croatia, STATS’ First World Cup Team Customer with STATS Edge™, Goes on Historic Run to Final

Andersen Tax & Legal Debuts in Ecuador

Kohler Co. Unveiled as Principal Partner of Manchester United

Henley & Partners Wins Mandate for Moldova Citizenship-by-Investment Program

Eutelsat Partners with Intelsat and SES in U.S. C-Band Spectrum Proposal

Corporate Social Responsibility Related News Releases and Story Ideas for Reporters, Bloggers and Media Outlets

Phase 3 Trial of NINLARO® (ixazomib) as Maintenance Therapy Met Primary Endpoint Demonstrating Statistically Significant Improvement in Progression-Free Survival in Patients with Multiple Myeloma Post-Transplant

Ingram Micro Strengthens Alliance With Salesforce India

Boyd Corporation Announces Agreement to be Acquired by Affiliates of Goldman Sachs from Genstar Capital

Toshiba Starts Shipment of UL508 Certified Photorelays for Industrial Control Equipment

Elevate to a Sportier Dimension. The New BMW 3 Series Gran Turismo Sport Launched in India

LF Logistics Works with Lanetix CRM to Accelerate Global Sales and Customer On-Boarding Processes

StackRoute - a Digital Transformation Partner for Corporates by NIIT Recognized as the Most Innovative Learning Partner for Enterprises

Tigo Introduces New Tigo Access Point (TAP) as UL-Certified Communication Device for TS4 Platform

EUSA Pharma: NICE Approves the Targeted Cancer Immunotherapy, QARZIBA®? (dinutuximab beta) to Treat Children with High-Risk Neuroblastoma

RSA Conference 2018 Asia-Pacific & Japan Announces Keynote Stage Line-up

SIRIN LABS Unveils the Design for the Dual-Screen FINNEY™, Introducing “Safe Screen” for the First Blockchain Smartphone

Yamalube – A Liquid Engine Component: Glass Harp

ExaGrid, Hyper-Converged Secondary Storage for Backup Leader, Reports Record Q2 Bookings and Revenue for Q2-2018

ResMed, Verily to Form Joint Venture to Help Reach Millions of Untreated Sleep Apnea Sufferers

 
TRENDING TOPICS
 
 
 
CITY NEWS
MORE CITIES
INDIA WORLD ASIA
Mbappe's France have quality to emulate ...
LS polls could be like world Cup footba...
Heavy rains paralyse normal life in Odis...
Dreaded criminal arrested in Bihar...
Differences in top EC at Mohun Bagan sur...
Demand for separate religion status for ...
More...    
 
 Top Stories
Kangra Municipal Council Chief resi... 
Jalandhar MP bats for optimum utili... 
Jalandhar police bans entry of cust... 
Amarinder okays pilot project for s... 
12 injured in road mishap... 
55-yr-old dies during Shrikhand Kai... 
Atrocities on Dalits on rise since ... 
Ban on construction in Shimla...